



Published in final edited form as:

Curr Opin Cardiol. 2009 July ; 24(4): 345–350. doi:10.1097/HCO.0b013e32832c1284.

Triglycerides as vascular risk factors: New Epidemiologic Insights For Current Opinion in Cardiology

William B. Kannel, MD¹ and Ramachandran S. Vasan, MD^{1,2}

¹The Framingham Heart Study, Framingham, MA

²Sections of Preventive Medicine and Cardiology, Department of Medicine, Boston University School of Medicine, Boston, MA

Abstract

Purpose of review—Targeting triglycerides as a vascular risk factor is justified because of the role of triglyceride-rich lipoproteins in atherogenesis. This review examines recent evidence connecting triglycerides with cardiovascular disease (CVD) in the context of advances in insights concerning the pathophysiology, population burden, and prognostic impact of fasting versus non-fasting values.

Recent Findings—Cross-sectional surveys indicate that mean triglyceride levels in the United States have increased in recent decades. While elevated fasting triglycerides are consistently associated with increased CVD risk, adjustment for other risk factors (especially HDL-C) substantially attenuates this relationship. A recent meta-analysis of 27 prospective studies of Western populations reported a triglyceride impact on CVD in *both sexes*, for both fasting and non-fasting values. Non-fasting triglycerides maintained an independent graded relationship with CVD in fully adjusted analyses, with elevated 4 hour post-prandial triglyceride imposing a 4.5-fold increment relative to lower levels.

Summary—Evidence supports a potential role for both fasting and non-fasting triglycerides as vascular risk factors, owing in part to the accompanying burden of atherogenic remnant particles, small dense LDL, reduced HDL-C and a high frequency of accompanying insulin resistance. Triglyceride-associated CVD risk occurs even in subjects with low LDL-C, and lowering both lipids provides more benefit than reducing LDL-C alone.

Introduction

The role of triglycerides (TG) in promoting cardiovascular disease (CVD) is still debated more than 60 years after a relationship was first postulated [1]. Recent data focusing on the potential importance of non-fasting TG levels seem to settle this debate by establishing a consistent strong relation of TG with CVD risk. In this review we discuss the changing epidemiology of TG in the community, summarize recent reports that underscore the importance of non-fasting values, and highlight the complexity in making causal inferences based on the associations noted given the interdependence of lipid particles.

New Insights into the role of TG in Atherogenesis

It is necessary to contemplate TG as “TG-rich lipoproteins” (commonly referred to as “TRL”) to emphasize the concept that the metabolism and turnover of TG in the circulation

may be as much (or more) a function of the composition of the other lipid and protein components of these particles as the fatty acid composition and concentrations of TG per se [2;3**]. Clinically, the two main components of TRL are the very-low density lipoproteins (VLDL) and chylomicrons. Since VLDL result from hepatic synthesis and chylomicrons are post-prandially produced by the gut, high TG are thought of as having an endogenous basis (increased hepatic synthesis) or an exogenous origin (dietary), or both. Regardless of the origin of TRL, the action of lipoprotein lipase in the capillary beds of the adipose tissue and muscles generates intermediate density lipoproteins from VLDL or chylomicron remnants [3**].

Remnant TRL levels can be very high in dyslipidemic conditions characterized by high TG, but are ordinarily also present in the normal post-prandial state. They are normally 'cleared' by the liver but in persons with CVD, TRL remain increased in the circulation beyond the usual 4–8 hours [4]. This failure to catabolize TRL efficiently appears to be linked to accelerated atherogenesis since TRL appear to be proinflammatory, cause endothelial dysfunction [5], upregulate expression of endothelial adhesion molecules and promote macrophage chemotaxis. TRL are especially prone to enter the arterial wall where they are ingested by macrophages (analogous to oxidized LDL), to then become foam cells [6–8]. Retention of these TRL in the vascular wall also traps the more atherogenic small LDL-C particles [6;9].

The pathogenic effects of higher TRL are intricately linked to those of higher levels of small dense LDL-C and lower concentrations HDL-C that often coexist [10]. This is because higher TRL are a key determinant of heterogeneity of LDL size; LDL particle size is strongly inversely related to the plasma triglyceride level [11]. This appears to result both from the derivation of small LDL particles from triglyceride-rich VLDL and from LDL-C remodeling involving neutral lipid exchange and lipolysis [12]. Smaller LDL particles appear less amenable to physiologic LDL clearance via the LDL receptor, which enhances their potential for avid binding to proteoglycans in the vascular wall. Furthermore, these small LDL particles appear to be more susceptible to oxidation, a property that further increases their atherogenicity [8]. Thus, plasma TG is an indirect indicator of the relative proportion of circulating small atherogenic LDL-C particles, and thus provides an indication of lipid particle size-related coronary risk. Persons with the same LDL-C can have a substantially different CVD risk depending on their plasma TG; those with elevated TG having a greater cardiovascular risk. The association of higher TG with greater levels of small-dense LDL is reversed when high TG levels are lowered with pharmacological treatment [13**].

TRL are also intimately associated with CETP-mediated exchange of TG with cholesterol esters in HDL-C particles. The TG-enriched HDL particles are removed rapidly by hepatic lipase [14]. Thus, higher TRL seem to accelerate the fractional catabolism of HDL ApoA-1 [15], a phenomenon further enhanced by concomitant higher levels of Apo CIII that typically accompany higher TG levels [16]. Hepatic steatosis that accompanies higher levels of TRL may mediate increased hepatic secretion of both Apo CIII and VLDL components [17;18]. As plasma TRL rise, clearance of apoAI and apoAII high-density lipoproteins is enhanced [19]. Smaller HDL particles are removed from the blood and catabolized more rapidly, limiting their efficiency in reverse cholesterol transport and consequently diminishing their cardioprotective effect [20].

These inter-relationships among the lipids are most evident in the context of the metabolic syndrome, a construct that reflects presence of both obesity and insulin resistance. Persons with high TG accompanied by reduced HDL-C can be presumed to have an atherogenic small LDL-C problem, particularly when accompanied by features of the metabolic

syndrome. It remains to be precisely estimated to what extent insulin resistance is responsible for the risk factor clustering that often accompanies 'atherogenic dyslipidemia' and the high CVD risk it imposes. However, it seems likely that insulin resistance is responsible for a substantial proportion of the clustering and attendant elevated CVD risk observed in persons with increased TG. Furthermore, high TRL occur in a metabolic milieu additionally characterized by greater thrombogenicity, inflammation, and diminished fibrinolysis, all of which can further compound the elevated CVD risk. Additionally, several recent reports [21;22] have highlighted the association of novel genetic loci with TG levels in the community, emphasizing the need for additional studies to better elucidate the biological basis of high TG states.

Burden of High TG in the Community

Two recent reports [23;24] evaluated National Health and Nutrition Examination Surveys (NHANES) conducted in 1999–2002 and 2003–2004, assessing trends in mean lipid levels in the United States (US) across these different cross-sectional surveys. The first report noted that mean TG in adults (20–74 years) increased from 114 mg/dl in 1976–1980 to 122 mg/dl in 1999–2002 [23]. In the second report, mean TG increased further to 129.5 mg/dl in 2003–4 [24]. It was estimated that approximately 13% of the US population (27 million people) have TG exceeding 200 mg/dl; 7% have both high TG and low HDL-C [24]. A more recent report from the National Lipid Association presented at the American Heart Association 2008 scientific sessions noted that mean U.S. TG continued to increase up to 2006 [25]. Compared to NHANES 1976–1980, data from surveys between 1999 and 2006 indicated that the proportion of individuals with isolated suboptimal TG (<150 mg/dl) increased 5-fold in people ages 60–74 years. About a third of adults have hypertriglyceridemia using this cutpoint (>150 mg/dl). This recent increase in mean TG in the US most likely reflects the increasing prevalence of obesity [25].

Association with Coronary Heart disease risk: Importance of Non-fasting TG

Many epidemiological investigations have explored the connection between TG and CHD risk, but the association had not been well quantified until recently. Primary data from the Reykjavik Study and European Prospective Investigation of Cancer Norfolk Study were used to provide such information [26**] and were incorporated into an updated meta-analysis of 27 additional prospective studies in Western populations comprised of 7,262,525 participants including 10,158 CHD cases. One important observation from this report was that, in contrast to prior investigations, year-to-year consistency of individual TG values was no different from those reported for blood pressure or for other lipids. In this meta-analysis, the risk factor-adjusted odds for developing CHD in subjects with upper tertile TG was 1.7 (relative to the lowest tertile), a risk ratio similar to that reported in Asian Pacific populations [27]. Furthermore, the data indicated an impact of TG on CHD risk in men as well as women, and also, distinct from other studies there was not much difference in the strength of the relation to CHD incidence in fasting versus non-fasting levels. Also, the continuous graded influence of TG to CHD incidence, like for other risk factors, extends down into what is regarded as the normal range with no indication of a critical value.

Another major recent study [28] focused on relating fasting TG and changes in fasting TG (over a 5-year period) to the incidence of CHD in 13,953 Israeli soldiers aged 26–45 years who were part of the MELANY [Metabolic, lifestyle, and nutrition assessment in young adults] Study. Over a follow-up of 10.5 years, men in the top TG quintile had a 4-fold adjusted-hazard of developing CHD relative to those in the lowest quintile ($P < 0.001$ for trend across quintiles) in analyses adjusting for multiple confounders including HDL-C. Of

note, men in whom TG levels increased 5 years from baseline experienced an over 3-fold greater risk of CHD relative to those in whom TG levels continued to be low [28].

Most prior population studies that initially noted associations between fasting plasma TG and CVD risk found that after adjustment for other risk factors (particularly HDL-C) TG was no longer an independent predictor [29–31]. Only a few studies found that TG maintained its independent predictive power when potential confounders were taken into account [32]. It is difficult to distinguish the effects of TG on CHD risk from that of low HDL-C, or from that of insulin resistance per se, both of which are strongly related to TG. Also, it is not clear whether it is appropriate to adjust for HDL-C which is strongly inversely correlated with TG and also biologically linked to insulin resistance in multivariable analyses. Austin suggests possible underestimation of the TG association with CHD because of the biological variation in its measurement and a the strong inverse correlation between TG and HDL-C making multivariable assessment of its net effect difficult to interpret [33].

Traditionally, TG have been measured in a fasting state because they are alleged to be too variable depending on when after a meal they are measured. Also, before the availability of direct assays, LDL-C estimation requires *fasting* TG values. It is important to note that the ubiquitous use of fasting TG for CVD risk evaluation was not based on epidemiological evidence indicating that fasting specimens are superior. Quite to the contrary, investigators have postulated that humans are in a postprandial state most of the day, and that atherosclerosis is a post-prandial phenomenon [4;34].

As noted above, most epidemiologic investigations that relied upon fasting TG concluded that they are only univariate predictors of vascular disease, the risk ratios becoming attenuated upon multivariable adjustment for HDL-C. Earlier meta-analyses of TG as a CVD predictor universally limited their evaluation to studies using fasting TG, which may have resulted in underestimation of the TG impact on vascular risk [35;36]. Because postprandial lipids and their partially hydrolyzed chylomicron and VLDL remnants appear to promote accelerated atherogenesis by adversely affecting endothelial function, and increasing numbers of atherogenic small LDL particles, thrombosis and inflammation., postprandial TG could provide more relevant information on vascular risk than fasting levels.

Recent reports directly address the matter by comparing fasting with non-fasting TG for CVD prediction [37**–41]. The Women's Health Study involving 26, 509 healthy American women followed 11-years for CVD development and mortality found that both fasting and non-fasting TG were associated with future CVD after adjustments for age, blood pressure, smoking and hormone-replacement therapy [37**]. Consistent with other studies in *fasting subjects*, further adjustment for total cholesterol and HDL-C markedly weakened the association with CVD. However, *non-fasting TG* maintained a strong independent relationship with future CVD in fully-adjusted analyses. The hazard ratios increased sequentially with increasing tertiles of non-fasting TG ; the upper tertile conferring a significant 2-fold increase in risk. Using TG measured 4 hours after a meal yielded the strongest (4.5-fold) relationship with CVD events [37**]. In a follow-up report [40], Mora et al compared the predictive utilities of fasting versus non-fasting values for other lipids noting that the predictive capability of HDL-C, total/HDL cholesterol ratio, and apolipoprotein A-1 did not differ by fasting versus non-fasting state. TG levels predicted better when non-fasting values were used, whereas total cholesterol, LDL-C, and non-HDL cholesterol, apolipoprotein B-100 and B-100/A-1 ratio proved less helpful for CVD risk evaluation when nonfasting concentrations were used [40].

Another long term prospective cohort study involving 7,587 women and 6,394 men in Copenhagen also found that non-fasting TG predicted vascular events after multivariable analysis [41]. The relationship was found in both sexes, and the highest risks were observed in persons with the highest postprandial TG (5 mmol/L). A subsequent report [38], extended these observations to stroke events. A third report [39], also based on the Copenhagen General Population Study, showed that postprandial lipid changes at any time are minimal compared to those in a fasting state and, indeed, found that at all times through the day the maximum increase in TG averaged only 0.3 mmol/L or ~ 27 mg/dL with ordinary eating.

Non-fasting TG has also been shown to be prospectively associated with increased CVD risk in Japanese men and women, after adjustment for both total cholesterol and HDL-C and an Asia Pacific Cohort Studies Collaboration with data from 26 cohorts, reported that non-fasting TG was a stronger predictor of CVD than fasting TG [27].

Studies also attest to the fact that TG measured after a standardized fat challenge predicts the presence of CHD [4]. As in the case of fasting TG, postprandial lipemia can be influenced by ethnicity, alcohol consumption, and menopausal status, which must be considered in triglyceride evaluation. However, an outpatient oral TG tolerance test has the disadvantage of increasing patient waiting time and effort and requires a *direct measurement of LDL* for comprehensive lipid evaluation.

TG as an indicator of insulin resistance

Increased TG and decreased HDL-C are key metabolic abnormalities in insulin resistance states, including the metabolic syndrome and type 2 diabetes. The TG/HDL cholesterol ratio has been advocated as a simple clinical indicator of insulin resistance that can serve as a convenient surrogate for evaluating the impact of insulin resistance on CHD incidence. The efficiency of blood lipids and their ratios (including total/HDL-C) for detection of insulin resistance and predicting its CHD hazard was recently investigated in 3014 Framingham Offspring Cohort participants [42*]. The correlation between the TG and the TG/HDL ratio was 0.93, indicating that for CHD risk assessment or evaluation of insulin resistance, measuring one is tantamount to using the other. The total /HDL-C ratio was also highly correlated with the TG/HDL ratio (0.82). Insulin resistance (HOMA-IR) was similarly correlated with the TG/HDL-C ratio ($r=0.48$), TG itself ($r=0.43$), and the total/HDL-C ratio ($r=0.43$). Comparison of the multivariable-adjusted impact of the lipids and their ratios on CHD incidence indicated that the lipid ratios are somewhat more predictive and discriminative than each of their lipid components [42]. However, TG (HR of 2.25, comparing the top tertile to the lowest) was almost as powerful a predictor of CHD as the TG/HDL lipid ratio (HR 2.54) and discriminated cases equally well. The total/HDL-C ratio fared only slightly better (HR 2.78 vs. 2.54). High TG/HDL-C and total/HDL-C ratios both indicated a degree of insulin resistance that warrant testing for impaired glucose tolerance or undetected diabetes. However, the impact of TG or the TG/HDL-C ratio on CHD incidence was only partially attributable to its association with insulin resistance. Surprisingly, CHD risk from insulin resistance appeared attributable as much to its association with an increased total/HDL-C ratio as to a high TG/HDL ratio [42*].

Efficacy of Treating Elevated TG

The current focus on LDL-C for assessing lipid risk and treatment seemingly needs broadening to accommodate the influence of other lipids. Given that the effect of TG on CVD incidence extends incrementally down into its “normal” range, the intensity of therapy to lower TG, especially when only modestly elevated, should be determined taking into account an individual's global CVD risk status.

Use of non-HDL-C, as suggested by the Adult Treatment Panel III [43], is a reliable non-fasting marker that provides the sum of all apolipoprotein B-containing lipoproteins including TRL. Non-HDL-C may be somewhat more effective for CVD prediction than LDL-C, especially when TG are increased [44**]. Accordingly, the NCEP ATP III recommends non-HDL-C as a secondary target of therapy when TG levels are ≥ 200 mg/dL, although a target level for TG-lowering therapy is not specified [43]. Alternatively, apolipoprotein-B itself might be measured as it reflects the presence of all pro-atherogenic particles [45].

At present, no clear evidence exists from intervention trials with a lipid-active drug that lowering TG, independent of a change in other CVD risk factors, reduces major CVD events. However, recent post-hoc analysis of PROVE IT-TIMI trial data [46] found that individuals treated with a high-dose statin who *achieved* a low TG on therapy had significantly fewer CVD events than those with a higher TG, even after adjusting for a lower LDL-C on therapy and other CVD risk factors. However, this finding does not necessarily imply that the extent of drug-induced TG reduction accounts for reduction in CVD events.

Although use of postprandial TG may have pathophysiologic support and demonstrated value for CVD prediction, no randomized trial data exist to demonstrate that *triglyceride reduction per se* lowers CVD incidence in *the absence of other lipid effects*.

Conclusions

High TG merits consideration as a prominent CVD risk factor because this often identifies candidates for CVD with insulin resistance, highly atherogenic small LDL remnant particles, lower values of HDL-C, and other manifestations of the metabolic syndrome. The CVD risk of elevated LDL-C is enhanced by coexistent hypertriglyceridemia and lowering both lipid fractions appears superior to reducing LDL-C alone. Recent epidemiological studies have underscored the associations of both fasting and non-fasting TG with CVD risk.

Acknowledgments

This work was supported through National Institutes of Health/National Heart, Lung, and Blood Institute Contract N01-HC-25195, and 2K24 HL04334 (Dr. Vasani)

References

1. Moreton JR. Atherosclerosis and Alimentary Hyperlipemia. *Science* 1947;106:190–191. [PubMed: 17749166]
2. Brinton EA, Nanjee MN, Hopkins PN. Triglyceride-rich lipoprotein remnant levels and metabolism: Time to adopt these orphan risk factors? *J Am Coll Cardiol* 2004;43:2233–2235. [PubMed: 15193685]
- 3**. Williams KJ. Molecular processes that handle -- and mishandle -- dietary lipids. *J Clin Invest* 2008;118:3247–3259. [PubMed: 18830418] Review article that details pathophysiological processes contributing to dyslipidemia with a focus on molecular events involved in lipid transport from the gut to the periphery and the liver.
4. Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. *Arterioscler Thromb* 1992;12:1336–1345. [PubMed: 1420093]
5. Nakamura T, Takano H, Umetani K, et al. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. *Atherosclerosis* 2005;181:321–327. [PubMed: 16039286]
6. Nordestgaard BG, Wootton R, Lewis B. Selective Retention of VLDL, IDL, and LDL in the Arterial Intima of Genetically Hyperlipidemic Rabbits In Vivo : Molecular Size as a Determinant of

- Fractional Loss From the Intima Inner Media. *Arterioscler Thromb Vasc Biol* 1995;15:534–542. [PubMed: 7749867]
7. Shaikh M, Wootton R, Nordestgaard BG, et al. Quantitative studies of transfer in vivo of low density, Sf 12–60, and Sf 60–400 lipoproteins between plasma and arterial intima in humans. *Arterioscler Thromb* 1991;11:569–577. [PubMed: 2029497]
 8. Tabas I, Williams KJ, Boren J. Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis: Update and Therapeutic Implications. *Circulation* 2007;116:1832–1844. [PubMed: 17938300]
 9. Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. *Arterioscler Thromb* 1994;14:1767–1774. [PubMed: 7947602]
 10. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. *Circulation* 1990;82:495–506. [PubMed: 2372896]
 11. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. *J Lipid Res* 2002;43:1363–1379. [PubMed: 12235168]
 12. Tan KC, Cooper MB, Ling KL, et al. Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance. *Atherosclerosis* 1995;113:273–287. [PubMed: 7605366]
 - 13**. Otvos JD, Collins D, Freedman DS, et al. Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. *Circulation* 2006;113:1556–1563. [PubMed: 16534013] Trial data confirming that plasma TG level is an indirect marker of circulating small atherogenic LDL-C particles, providing an indication of lipid particle size-related coronary risk. The data demonstrate that persons with the same LDL-C can have a substantially different CVD risk depending on their plasma TG levels; those with elevated TG have greater cardiovascular risk. Also showed that the association of elevated TG with greater levels of small-dense LDL is reversed when TG levels are lowered with pharmacological treatment.
 14. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. *Clin Biochem* 2003;36:421–429. [PubMed: 12951168]
 15. Ji J, Watts GF, Johnson AG, et al. High-Density Lipoprotein (HDL) Transport in the Metabolic Syndrome: Application of a New Model for HDL Particle Kinetics. *J Clin Endocrinol Metab* 2006;91:973–979. [PubMed: 16368749]
 16. Chan DC, Nguyen MN, Watts GF, Barrett PH. Plasma Apolipoprotein C-III Transport in Centrally Obese Men: Associations with Very Low-Density Lipoprotein Apolipoprotein B and High-Density Lipoprotein Apolipoprotein A-I Metabolism. *J Clin Endocrinol Metab* 2008;93:557–564. [PubMed: 18000086]
 17. Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. *Diabetologia* 2006;49:755–765. [PubMed: 16463046]
 18. Matikainen N, Manttari S, Westerbacka J, et al. Postprandial Lipemia Associates with Liver Fat Content. *J Clin Endocrinol Metab* 2007;92:3052–3059. [PubMed: 17488790]
 19. Brinton EA, Eisenberg S, Breslow JL. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. *J Clin Invest* 1991;87:536–544. [PubMed: 1899429]
 20. Das DK. Cardioprotection With High-Density Lipoproteins: Fact or Fiction? *Circ Res* 2003;92:258–260. [PubMed: 12595335]
 21. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. *Nat Genet* 2009;41:56–65. [PubMed: 19060906]
 22. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. *Nat Genet* 2008;40:189–197. [PubMed: 18193044]

23. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in Serum Lipids and Lipoproteins of Adults, 1960–2002. *JAMA* 2005;294:1773–1781. [PubMed: 16219880]
24. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003–2004. *American Heart Journal* 2008;156:112–119. [PubMed: 18585505]
25. Trends in lipid fractions and antidy lipidemic use among US adults: findings from the National Health and Nutrition Examination Survey II, III, and 1999–2006. *Circulation* 2009;118:S470.
- 26**. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies. *Circulation* 2007;115:450–458. [PubMed: 17190864] A large meta-analysis of prospective studies in Western populations comprised of 7, 262,525 participants and 10,158 CHD cases. Important observations from this report are the year-to-year consistency of individual TG values comparable to the variability reported for blood pressure or other lipids. Furthermore, the data indicated an impact of TG on CHD risk in men as well as women, and also, compares the strength of the relation to CHD incidence for fasting versus non-fasting TG levels. Also, examines the graded influence of TG to CHD incidence looking for a critical threshold value (none was observed).
27. Asia Pacific Cohort Studies Collaboration. Serum Triglycerides as a Risk Factor for Cardiovascular Diseases in the Asia-Pacific Region. *Circulation* 2004;110:2678–2686. [PubMed: 15492305]
28. Tirosh A, Rudich A, Shochat T, et al. Changes in Triglyceride Levels and Risk for Coronary Heart Disease in Young Men. *Ann Intern Med* 2007;147:377–385. [PubMed: 17876021]
29. Albrink MJ, Man EB. Serum triglycerides in coronary artery disease. *Arch Intern Med* 1959;103:4–8.
30. Fager G, Wiklund O, Olofsson SO, et al. Multivariate analyses of serum apolipoproteins and risk factors in relation to acute myocardial infarction. *Arteriosclerosis* 1981;1:273–279. [PubMed: 7295199]
31. Goldstein JL, Hazzard WR, Schrott HG, et al. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. *J Clin Invest* 1973;52:1533–1543. [PubMed: 4718952]
32. Bainton D, Miller NE, Bolton CH, et al. Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men: The Caerphilly and Speedwell Collaborative Heart Disease Studies. *Br.Heart J* 1992;68:60–66. [PubMed: 1355351]
33. Austin MA. Plasma triglyceride and coronary heart disease. *Arterioscler Thromb* 1991;11:2–14. [PubMed: 1987999]
34. Zilversmit DB. Atherogenesis: a postprandial phenomenon. *Circulation* 1979;60:473–485. [PubMed: 222498]
35. Abdel-Maksoud MF, Hokanson JE. The complex role of triglycerides in cardiovascular disease. *Semin.Vasc Med* 2002;2:325–333. [PubMed: 16222622]
36. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. *J Cardiovasc Risk* 1996;3:213–219. [PubMed: 8836866]
- 37**. Bansal S, Buring JE, Rifai N, et al. Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women. *JAMA* 2007;298:309–316. [PubMed: 17635891] A recent reports directly comparing fasting with non-fasting TG for CVD prediction in the Women's Health Study for CVD development and mortality after adjustments for age, blood pressure, smoking and hormone-replacement therapy. Also contains a good review of evidence on predictive utility of fasting versus non-fasting TG levels.
38. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting Triglycerides and Risk of Ischemic Stroke in the General Population. *JAMA* 2008;300:2142–2152. [PubMed: 19001625]
39. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and Nonfasting Lipid Levels: Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction. *Circulation* 2008;118:2047–2056. [PubMed: 18955664]

40. Mora S, Rifai N, Buring JE, Ridker PM. Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events. *Circulation* 2008;118:993–1001. [PubMed: 18711012]
41. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women. *JAMA* 2007;298:299–308. [PubMed: 17635890]
- 42*. Kannel WB, Vasani RS, Keyes MJ, et al. Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). *Am J Cardiol* 2008;101:497–501. [PubMed: 18312765] Recent Framingham study investigation of the predictive utility of blood lipids and their ratios (including total/HDL-C) for detection of insulin resistance and predicting its CHD hazard. Challenges the notion that TG/HDL ratio is a superior indicator of insulin resistance and its CHD consequences.
43. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486–2497. [PubMed: 11368702]
- 44**. Ridker PM, Rifai N, Cook NR, et al. Non-HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women. *JAMA* 2005;294:326–333. [PubMed: 16030277] Report suggesting use of non-HDL-C as a reliable non-fasting marker that provides the sum of all apolipoprotein B-containing lipoproteins including TRL, and that non-HDL-C may be somewhat more effective for CVD prediction than LDL-C, especially when TG are increased.
45. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation. *J Am Coll Cardiol* 2008;51:1512–1524. [PubMed: 18402913]
46. Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT/TIMI 22 trial. *J Am Coll Cardiol* 2008;51:724–730. [PubMed: 18279736]